Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156256 | 0.90 | NOTUM (0.82) | NOTUMTP53MAPTMEN1KMT2A | |
| SCHEMBL429841 | 0.86 | NOTUM (0.76) | NOTUMNPC1TP53MAPTRAB9A | |
| SCHEMBL16600509 | 0.85 | NOTUM (0.73) | NOTUMNPC1TP53MAPTRAB9A | |
| SCHEMBL6072422 | 0.83 | NOTUM (0.73) | NOTUMNPC1TP53MAPTRAB9A | |
| SCHEMBL17368391 | 0.82 | NOTUM (0.69) | NOTUMNPC1TP53MAPTRAB9A | |
| SCHEMBL15448489 | 0.82 | NOTUM (0.69) | NOTUMNPC1TP53MAPTRAB9A | |
| SCHEMBL15108132 | 0.82 | NOTUM (0.69) | NOTUMNPC1TP53MAPTRAB9A | |
| SCHEMBL13345024 | 0.82 | KDM4E (0.83) | NOTUMNPC1TP53MAPTRAB9A | |
| SCHEMBL615232 | 0.81 | NOTUM (0.69) | NOTUMNPC1TP53MAPTRAB9A | |
| SCHEMBL5009163 | 0.81 | NOTUM (1.00) | NOTUMMAPTKDM4ECYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749355-B1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | UNIV MIAMI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-10959984-B2 | Methods for treating cancer with RORγ inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2019157065-A9 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2019157065-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2018138362-A1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20180085348-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-7321063-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321063-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-22 | — | — | US | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| WO-2007026097-A1 | NOVEL INDOLE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | NOTUM 2880/4885NPC1 485/4885TP53 4692/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | NOTUM 4762/4885NPC1 2037/4885TP53 4252/4885 |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | SLC6A2, TPH1, SLC6A3 | NOTUM 2517/4885NPC1 701/4885TP53 4863/4885 |
| US-20180085348-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | RORB, RORA, RORC | NOTUM 3489/4885NPC1 2297/4885TP53 495/4885 |
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | NOTUM 1823/4885NPC1 13/4885TP53 4092/4885 |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SQOR, QSOX1, SQLE | NOTUM 1262/4885NPC1 3484/4885TP53 4869/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | NOTUM 1437/4885NPC1 4158/4885TP53 4055/4885 |
| US-10959984-B2 | Methods for treating cancer with RORγ inhibitors | RORB, RORC, RORA | NOTUM 3446/4885NPC1 1579/4885TP53 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.